国产司帕沙星片治疗117例急性细菌性感染

目的:评价国产司帕沙星片治疗急性细菌性感染的临床疗效与安全性。方法:以国产洛美沙星片为对照药进行随机对照研究,共治疗各种细菌性感染231例,其中司帕沙星组 117例、洛美沙星组 114例。司帕沙星200~300 mg,1次/d口服,疗程 5~14 d;洛美沙星 300mg,2次/d口服,疗程 5~14 d。结果:司帕沙星组与对照组的痊愈率和有效率分别为84.62%与74.56%和 94.87%与 92.98%。细菌清除率分别为94.28%和 92.02%。组间比较差异无显著性(P＞0.05)。两组的不良反应发生率分别为7.69%和 11.40%(P＞0.05),反应多呈轻度,勿需处理可自行缓解。结论:司帕沙星抗菌谱广,抗菌活性强,为治疗中、轻度急性细菌性感染安全有效的口服抗菌药物。     

口服国产司帕沙星片治疗急性细菌性感染多中心随机对照研究

目的 评价国产司帕沙星片治疗急性细菌性感染的临床疗效与安全性。方法 以国产洛美沙星片为对照药进行随机对照研究，共治疗各种细菌性感染231例，其中司帕沙星117例、洛美沙星组114例。司帕沙星200－300mg，每日1次口服，疗程5-14d；洛美沙星300mg，每日2次口服，疗程5－14d。结果 司帕沙星组与对照组的痊愈率和有效率分别为84．62％与74．56％和94．87％与92．98％。细菌清除率分别为94．28％和92．02％。组间比较差异无显性（P＞0．05）。两组的不良反应发生率分别为7．69％和11．40％（P＞0．05），反应多呈轻度，勿需处理可自行缓解。结论 司帕沙星抗菌谱广，抗菌活性强，为治疗中、轻度急性细菌性感染安全有效的口服抗菌药物。     

司帕沙星与洛美沙星随机对照治疗82例呼吸系统感染临床评价

目的用司帕沙星与洛美沙星随机对照治疗急性呼吸系统细菌性感染,对前者进行安全性及有效性评价.方法剂量为司帕沙星200mg,QD,疗程5～14天,洛美沙星200mg Bid,餐后1小时服用,疗程5～14天.结果共完成82例(试验组42例,其中1例只计不良反应,对照组40例),病种包括化脓性扁桃腺炎、扁桃腺周围脓肿、急慢性支气管炎、肺炎、支气管扩张症伴感染等,试验组与对照组对不同感染病种患者的有效率分别为87.80%与73.12%,试验组、对照组不同细菌感染者的有效率为87.18%与73.68%,组间无显著性差异(P＞0.05),两组细菌清除率分别为92.31%与81.58%,不良反应发生率分别为9.52%与5.00%,差异无显著性(P＞0.05).77株细菌对司帕沙星与洛美沙星高敏率为81.12%与67.53%.结论司帕沙星抗菌谱广,抗菌活性强,为一治疗轻、中度急性呼吸系统细菌性感染安全有效的口服药物.     

国产洛美沙星治疗细菌性感染43例

本文报道用国产洛美沙星治疗各种细菌性感染43例,其中11例与依诺沙星治疗组10例作随机对照,剂量均为0.2g,每日三次口服.疗程5～10天.结果随机对照组洛美沙星与依诺沙星临床治疗分别为100%和40%(P<0.05).洛美沙星开放组32例,临床疗效90.63%.全部43例(随机组11例加开放组32例)的总临床有效率为93.02%.本文证明国产洛美沙星对细菌性感染有很好的疗效.     

国产司帕沙星与洛美沙星治疗急性细菌性感染的随机对照研究

为评价国产司帕沙星片的临床疗效与安全性,采用洛美沙星片为对照,共治疗急性细菌性感染７０例,其中试验组与对照组各３５例。司帕沙星２００ｍｇＱＤ,洛美沙星３００ｍｇＢｉｄ,疗程７～１４日。结果显示,试验组和对照组的临床痊愈率均为８０．００％,有效率分别为９４．２９％和９７．１４％。细菌清除率分别为９３．９４％和９３．７５％,不良反应发生率分别为８．７５％和５．７１％。以上结果两组比较均无统计学差异（Ｐ     

国产洛美沙星治疗急性细菌性感染的随机对照临床研究

应用两种国产洛美沙星胶囊治疗急性细菌性感染405例,其中随机对照组103对、开放试验组199例.两药均为200mg每日两次口服,疗程7～14日.结果表明,试验组与对照组的痊愈率和有效率分别为76.70%与80.58%和95.15%与92.23%.细菌清除率分别为90.20%与90.91%.以上结果组间比较均无统计学差异(P＞0.05).开放组痊愈率和有效率分别为79.40%与93.47%,细菌清除率为96.15%.试验组与对照组的不良反应发生率分别为6.80%与5.83%(P＞0.05),开放组为5.03%.不良反应多呈轻度,勿需处理可自行缓解.以上结果提示,两种国产洛美沙星胶囊同样安全、有效.     

司帕沙星注射液与氧氟沙星注射液治疗急性呼吸道感染的随机对照试验

目的评价司帕沙星注射液治疗急性中、重度呼吸道感染的有效性与安全性.方法采用多中心随机对照试验.试验药司帕沙星每次200mg,静脉滴注,每日一次;对照药氧氟沙星每次200mg,静脉滴注,每日二次,疗程均为7-14天.试验组和对照组各30例.结果两组的治愈率分别为33.33%与26.67%,有效率分别是80.00%与76.67%.细菌清除率分别是89.66%与89.29%.药物不良反应发生率分别是13.33%与16.67%.本组病例未见光敏反应.以上结果经统计学处理差异均无统计学意义(P＞0.05).结论司帕沙星注射液是治疗急性呼吸道感染的一种有效药物.     

司帕沙星和洛美沙星的随机对照临床研究

司帕沙星是一种消除半衰期长,组织渗透力强,抗菌谱广的新型喹诺酮类抗菌药物。本文以洛美沙星为对照药,采用随机对照试验考察国产司帕沙星的临床疗效和不良反应。司帕沙星200mgQD疗程5－10天,治疗呼吸系统、泌尿系统、皮肤软组织、烧伤创面感染以及伤寒等共45例,临床痊愈率和有效率为77．78％和91．11％;对照药洛美沙星治疗各种感染的临床痊愈率和有效率为67．44％和86．65％（P＞0．05）;司帕沙星治疗细胞清除率和阴转率为92．50％和92．30％;洛美沙星组为86．84％和86．65％（P＞0．05）;所分离的临床分离株对司帕沙星的敏感率为93．59％,对照组为91．03％（P＞0．05）。由上可知,司帕沙星是一种使用方便,可用于治疗各系统感染、安全有效的抗感染药物。     

甲磺酸帕珠沙星治疗急性细菌性感染的临床研究

目的：评价甲磺酸帕珠沙星氯化钠注射液治疗临床常见急性细菌性感染性疾病的有效性及安全性。方法：用随机、双盲、对照试验法，甲磺酸帕珠沙星注射液（治疗组）每次300mg，盐酸左氧氟沙星注射液（对照组）每次400mg，均每日1次，静脉滴注。疗程均7天，共入选病例104例，治疗组及对照组各52例。结果：2组临床总有效率分别为98．08％和96．15％。药物不良反应分别为5．57％和11．54％。结论：甲磺酸帕珠沙星注射液治疗急性细菌性感染安全、有效。     

国产洛美沙星治疗细菌性感染43例

本文报道用国产洛美沙星治疗各种细菌性感染４３例，其中１１例与依诺沙星治疗组１０例作随机对照，剂量均为０．２ｇ，每日三次口服。疗程５￣１０天。结果随机对照组洛美沙星与依诺沙星临床治疗分别为１００％和４０％（Ｐ〈０．０５）。洛美沙星开放组３２例，临床疗效９０．６３％。全部４３例（随机组１１例加开放组３２例）的总临床有效率为９３．０２％。本文证明国产洛美沙星对性感染有很好的疗效。     

Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis. Sparfloxacin Multicenter AMS Study Group

Five hundred four patients were enrolled in a randomized, double-masked, multicenter study comparing the efficacy and tolerability of a 10-day regimen of sparfloxacin with a 14-day regimen of clarithromycin in the treatment of acute maxillary sinusitis. Two hundred fifty-two patients received sparfloxacin as a single 400-mg dose on day 1 and 200 mg once daily for 9 additional days, and 252 patients received clarithromycin 500 mg twice daily for 14 days. In the all-treated population, clinical success was observed at 6 to 10 days after therapy in approximately 82% of the patients in each treatment group. A total of 430 patients met the inclusion criteria for clinical assessment. The success rates in these patients were also comparable, at 83.1% and 83.4% for the sparfloxacin and clarithromycin groups, respectively. Sustained clinical success rates in the all-treated population 3 to 4 weeks after therapy were 71.6% for the sparfloxacin group and 68.6% for the clarithromycin group. All treated patients were included in the tolerability analysis. The frequency of adverse events in the clarithromycin and sparfloxacin groups was 57.9% and 48.4%, respectively. The most frequently noted adverse events were diarrhea, photosensitivity reaction, taste perversion, nausea, and abdominal pain; >96% of adverse events in the sparfloxacin group and 94% of adverse events in the clarithromycin group were of mild or moderate severity. Among adverse events at least possibly related to study drug, photosensitivity reaction was more common in the sparfloxacin group (9.5% vs. 0.4%), whereas taste perversion (8.7% vs. 0.8%) and abdominal pain (3.6% vs. 1.6%) were more common in the clarithromycin group. Thus the sparfloxacin's more convenient regimen was as effective as clarithromycin in the treatment of acute bacterial maxillary sinusitis, and the overall frequency of adverse events with sparfloxacin was comparable to that with clarithromycin.     

甲磺酸帕珠沙星注射液治疗急性细菌性感染39例

目的：评价国产甲磺酸帕珠沙星注射液治疗中、重度急性细菌感染的临床疗效与安全性。方法：采用随机对照试验设计,以左氧氟沙星为阳性对照药,甲磺酸帕珠沙星500mg,左氧氟沙星300mg,均为每12小时静脉滴注一次,每日两次,疗程为7～10天。结果：本研究共纳入39例,其中甲磺酸帕珠沙星组20例,左氧氟沙星19例。疗程结束时两组的痊愈率分别为70.00%和68.42%,有效率分别为85.00%和78.95%,细菌清除率分别为91.67%和100%。以上结果两组组间比较差异均无统计学差异。两组的不良反应发生率分别为4/20和1/19,主要表现为局部刺激及转氨酶升高等。结论：国产甲磺酸帕珠沙星注射液治疗中重度细菌感染疗效确切,安全性好。     

头孢丙烯与头孢克洛随机对照治疗下呼吸道感染患者的临床评价

目的　评价头孢丙烯与头孢克洛随机对照治疗下呼吸道感染的疗效和安全性。方法　轻、中度下呼吸道感染患者 12 0例随机分成两组 ,头孢丙烯组 6 2例予头孢丙烯 5 0 0mg ,口服 ,2次 /d ;头孢克洛组 5 8例予头孢克洛5 0 0mg ,口服 ,3次 /d。两组均以 7～ 14天为 1个疗程。结果　头孢丙烯组与头孢克洛组的临床有效率分别为 91.9%与 89.7% (P >0 .0 5 ) ,细菌消除率为 89.8%与 88.9% (P >0 .0 5 ) ,两组均无明显不良反应。结论　头孢丙烯可作为治疗轻、中度下呼吸道感染有效和安全的抗生素     

莫西沙星治疗腹腔内感染的药物学研究

目的：探讨莫西沙星注射液应用在中重度急性腹腔感染治疗中的临床疗效与安全性。方法：共纳入31例患者,随机分为罗氏芬加甲硝唑治疗组（对照）,罗氏芬2g,每日1次,甲硝唑0．5g,每日2次;莫西沙星治疗组,莫西沙星400mg,每日1次,均为静脉滴注,疗程为7～14天。结果：两组的痊愈率分别为80％和81．25％,有效率分别为86．67％和87．5％,细菌清除率分别为91．67％与90％。组间比较差异均无统计学意义。两组的不良反应发生分别为2／15和1／16,主要表现为局部刺激及转氨酶升高等。结论：莫西沙星注射液治疗中重度腹腔细菌感染疗效确切,安全性好。     

头孢地尼与头孢特仑酯随机对照治疗细菌性感染

目的 :以头孢地尼和头孢特仑酯随机对照治疗急性轻中度呼吸道、泌尿道及皮肤软组织感染 ,评价头孢地尼的疗效及安全性。方法 :31例患者接受头孢地尼 10 0～ 2 0 0mg ,每日 3次 ;35例接受头孢特仑酯 10 0～ 2 0 0mg ,每日 3次 ,疗程 7～ 14d。结果 :试验组和对照组痊愈率和有效率分别为 74 .2 %、80 .0 % (P >0 .0 5 )与 96 .8%、97.1% (P >0 .0 5 )。两组的细菌阳性率、清除率分别为 87.1%、85 .7% (P >0 .0 5 )和 96 .3%、93.3% (P >0 .0 5 )。临床分离的 5 7株致病菌对头孢地尼、头孢特仑酯、头孢克肟、头孢克洛、阿莫西林和环丙沙星的敏感率分别为 87.7%、98.2 %、4 7.4 %、82 .5 %、4 3.9%和 6 3.2 % ;头孢地尼与头孢特仑酯、头孢克洛相比差异无显著性 (P >0 .0 5 ) ,但与头孢克肟、阿莫西林和环丙沙星相比差异有显著性 (P <0 .0 5 )。两组不良反应发生率分别为 4 .9%和 9.1% (P >0 .0 5 )。结论 :头孢地尼治疗轻、中度细菌感染安全、有效。     

加替沙星注射液治疗急性尿路感染的多中心随机对照临床研究

目的：评价国产加替沙星注射液治疗急性尿路感染的临床疗效与安全性。方法：以左氟沙星注射液为对照,采用多中心随机对照试验设计,两药均为200mg静脉滴注,Q12h,疗程7～10日。结果：加替沙星组与左氟沙星组的痊愈率和总有效率分别为65．79％与83．33％和94．74％与97．62％,细菌清除率分别为87．88％和96．77％,不良反应发生率分别为9．30％和8.89％,以上结果两组间比较差异均无统计学意义。两组不良反应均主要为轻度恶心、呕吐、失眠、局部刺激及肝功转氨酶增高。结论：国产加替沙星注射液治疗急性尿路感染疗效确切,安全性较好。     

芦氟沙星与氧氟沙星随机对照治疗细菌性感染126例

目的 :评价芦氟沙星治疗细菌性感染的有效性和安全性。方法 :随机对照芦氟沙星和氧氟沙星治疗细菌性感染 12 6例 ,其中呼吸道感染 6 4例 ,泌尿道感染 6 2例。剂量用法 :芦氟沙星口服 ,第 1日用量 4 0 0mg每日 1次 ,第 2日至疗程结束用量 2 0 0mg每日 1次 ;氧氟沙星 ,2 0 0～ 30 0mg每日 2次。疗程为 5～ 14d。 结果 :芦氟沙星与氧氟沙星临床疗效评价病例数分别为 6 5例和 6 1例 ,两药临床有效率分别为 92 .3% 93.4 % ,细菌阳性率分别为 87.7%和 83.6 % ,细菌清除率分别为91.2 %和 94 .1% ,不良反应发生率分别为 7.7%和 8.2 %。以上结果经统计学处理差异均无显著性 (P >0 .0 5 )。结论 :研究表明芦氟沙星治疗细菌性感染有效、安全     

Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Sparfloxacin Multicenter Uncomplicated Urinary Tract Infection Study Group.

Urinary tract infection (UTI) is a common illness, with > or =30% of all women experiencing a UTI during their lifetime. Less than a decade ago, the standard therapy for acute uncomplicated UTIs involved treatment with > or =7 days of an antibacterial agent, but recent studies using a variety of newly introduced antibiotics, including the fluoroquinolones, have demonstrated that a 1- to 5-day treatment regimen can be equally effective. This randomized, double-masked, multicenter study was conducted to compare the efficacy and tolerability of a single dose of sparfloxacin with those of a 3-day regimen of sparfloxacin and a 7-day regimen of ciprofloxacin in the treatment of women with community-acquired acute uncomplicated urinary tract infection. A total of 1175 women were enrolled; 395 received sparfloxacin as a single 400-mg dose on day 1, 394 received sparfloxacin as a 400-mg loading dose on day 1 followed by 200 mg once daily for 2 additional days, and 386 received ciprofloxacin 250 mg twice daily for 7 days. Patients were comparable with respect to demographic characteristics and underlying conditions. A total of 954 patients were clinically assessable; 490 of these were also bacteriologically assessable. All patients treated were included in the tolerability analysis. Escherichia coli (75.4%), Klebsiella pneumoniae (4.9%), Enterococcus faecalis (4.6%), and Staphylococcus saprophyticus (4.1%) were the most commonly isolated organisms. In the all-treated population, clinical success was achieved 5 to 9 days after therapy in 91.8%, 92.2%, and 91.6% of patients in the single-dose sparfloxacin, 3-day sparfloxacin, and 7-day ciprofloxacin groups, respectively; bacteriologic success was observed in 91.7%, 92.6%, and 96.6% of those in the 3 groups. Sustained clinical success rates 4 to 6 weeks after therapy were 76.6%, 80.2%, and 79.5% in the single-dose sparfloxacin, 3-day sparfloxacin, and 7-day ciprofloxacin groups, respectively; sustained bacteriologic success rates were 80.7%, 90.1%, and 92.6%. The most common adverse events were nausea, headache, vaginal thrush, dizziness, and diarrhea; >92% of adverse events were mild or moderate in severity. The 2 drugs had comparable frequencies of adverse events, except for photosensitivity, which occurred in 3.3% of the 3-day sparfloxacin group, 1.3% of the single-dose sparfloxacin group, and 0.3% of the ciprofloxacin group (P = 0.005). The 3-day sparfloxacin regimen was effective and well tolerated. The initial response to single-dose sparfloxacin treatment was comparable to the response to the other 2 regimens, but the single-dose regimen proved less effective over time, with higher rates of clinical recurrence and bacteriologic relapse. Sparfloxacin provides an alternative to ciprofloxacin for patients with acute uncomplicated urinary tract infection who are not at risk for photosensitivity reactions or adverse events associated with a prolonged corrected QT interval.